The Supreme Court rejected an emergency appeal challenging mifepristone's availability through mail delivery, preserving access to the abortion pill across the nation. The decision came Thursday as the Court released two additional unanimous opinions.
The case centered on mifepristone, the first drug in a two-drug abortion regimen approved by the FDA in 2000. Anti-abortion groups sought to restrict or eliminate mail-based distribution of the medication, arguing the FDA's 2023 expansion of remote dispensing violated federal law.
The Court's action effectively blocked lower court rulings that would have severely curtailed access to mifepristone. The underlying dispute involves the FDA's authority to modify medication approval conditions and the scope of the Administrative Procedure Act, which governs how federal agencies make regulatory changes.
This decision preserves the status quo established when the Biden administration expanded access to mifepristone via mail in December 2022. Under current FDA regulations, mifepristone can be prescribed via telehealth and mailed to patients, substantially increasing availability compared to pre-expansion practices that required in-person pickup.
The practical implications extend across the healthcare industry. Telehealth providers, pharmacies, and abortion clinics rely on mail delivery for mifepristone distribution in states where abortion remains legal post-Dobbs v. Jackson Women's Health Organization. Restricting mail access would have created significant barriers for patients in rural areas and states with limited in-person abortion services.
The Court's rejection of the emergency appeal signals skepticism toward efforts to challenge the FDA's regulatory authority through expedited proceedings. The two unanimous opinions released simultaneously addressed separate legal questions but reinforced the Court's methodical approach to disputed agency actions.
Anti-abortion advocates promised continued litigation, suggesting they would pursue alternative legal strategies to restrict mifepristone access through different legal theories or venues. Their efforts may focus on state-